Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer

  • Original Paper
  • Published:
Pathology & Oncology Research

Abstract

Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in several human cancers and associated with tumor progression, invasion and metastasis. However, the correlation between PRL-3 expression and clinical outcome in ovarian cancer has not been studied. In the present study, we investigated the expression of PRL-3 in 119 ovarian cancers and 30 normal ovarian tissues by immunohistochemistry with an anti-PRL-3 mouse monoclonal antibody 3B6, and analyzed its relationship with clinicopathologic factors and survival. The results demonstrated that PRL-3 expression was significantly higher in ovarian cancers compared to normal ovarian tissues (P < 0.001). PRL-3 expression is not correlated with patient age, menstruation, tumor size, histological type, residual tumor, or other clinical findings. The patients with PRL-3-positive tumors had a significant poor prognosis than those with PRL-3-negative tumors. Univariate analysis identified PRL-3 expression as a poor outcome predictor (HR 1.925, 95% CI, 1.046–3.544, P = 0.035). Multivariate analysis indicated that PRL-3 expression was an independent prognostic factor of borderline significance (HR 1.695, 95% CI, 0.914–3.145, P = 0.094). Our results suggest that PRL-3 may serve as a valuable marker for diagnosis of ovarian cancer and as a potential independent prognostic factor for ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

PRL-3:

phosphatase of regenerating liver-3

OS:

overall survival

HR:

hazard ratio

TP:

TP based chemotherapy (combination of taxol and cisplatin)

CAP:

CAP based chemotherapy (combination of cyclophosphamide, cisplatin and adriamycin)

References

  1. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529

    Article  CAS  PubMed  Google Scholar 

  2. Zurawski VR Jr, Orjaseter H, Andersen A et al (1988) Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 42:677–680

    Article  PubMed  Google Scholar 

  3. Mastropaolo W, Fernandez Z, Miller EL (1986) Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation. Clin Chem 32:2110–2111

    CAS  PubMed  Google Scholar 

  4. Takahashi K, Shibukawa T, Moriyama M (1986) Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer-a study on 674 patients. Jpn J Surg 16:305–310

    Article  CAS  PubMed  Google Scholar 

  5. Lyon M, Ducruet A, Wipf P, et al (2002) Dual-specificity phosphates as targets for antineoplastic agents. Nat Rev Drug Discov 1:961–976

    Article  CAS  PubMed  Google Scholar 

  6. Zeng Q, Hong W, Tan YH (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 244:421–427

    Article  CAS  PubMed  Google Scholar 

  7. Diamond RH, Cressman DE, Laz TM, et al (1994) PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 14:3752–3762

    CAS  PubMed  Google Scholar 

  8. Werner SR, Lee PA, DeCamp MW, et al (2003) Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases. Cancer Lett 202:201–211

    Article  CAS  PubMed  Google Scholar 

  9. Polato F, Codegoni A, Fruscio R, et al (2005) PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 11:6835–6839

    Article  CAS  PubMed  Google Scholar 

  10. Zeng Q, Dong JM, Guo K, et al (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63:2716–2722

    CAS  PubMed  Google Scholar 

  11. Wu X, Zeng H, Zhang X (2004) Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 23:23–27

    Google Scholar 

  12. Guo K, Li J, Tang JP, et al (2004) Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol Ther 3:945–951

    Article  CAS  PubMed  Google Scholar 

  13. Li J, Guo K, Koh VW, et al (2005) Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin Cancer Res 11:2195–2204

    Article  CAS  PubMed  Google Scholar 

  14. Guo K, Li J, Tang JP, et al (2008) Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 7

  15. Peng L, Li Y, Meng L, et al (2004) Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3. Hybrid Hybridomics 23:23–27

    Article  CAS  PubMed  Google Scholar 

  16. Peng L, Ning J, Meng L, et al (2004b) The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 130:521–526

    Article  CAS  PubMed  Google Scholar 

  17. Wang L, Peng L, Dong B, et al (2006) Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 17:1517–1522

    Article  CAS  PubMed  Google Scholar 

  18. Wang Y, Li ZF, He J, et al (2007) Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis. Int J Colorectal Dis 22:1179–1184

    Article  PubMed  Google Scholar 

  19. Miskad UA, Semba S, Kato H, Yokozaki H (2004) Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71:176–184

    Article  CAS  PubMed  Google Scholar 

  20. Miskad UA, Semba S, Kato H, et al (2007) High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 450:303–310

    Article  CAS  PubMed  Google Scholar 

  21. Stephens B, Han H, Gokhale V, et al (2005) PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 4:1653–1661

    Article  CAS  PubMed  Google Scholar 

  22. Han H, Bearss DJ, Browne LW, et al (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62:2890–2896

    CAS  PubMed  Google Scholar 

  23. Stephens B, Han H, Hostetter G, et al (2008) Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther 7:202–210

    Article  CAS  PubMed  Google Scholar 

  24. Kato H, Semba S, Miskad UA, et al (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10:7318–7328

    Article  CAS  PubMed  Google Scholar 

  25. Radke I, Gotte M, Kersting C, et al (2006) Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer 95:347–354

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National 973 Program (2009CB521805), National Natural Sciences Foundation of China (30671024) and Natural Science Foundation of Beijing (5072015). We thank Dr. Like Qu for critical reading of the manuscript, Dr. Jiyou Li for histopathological diagnosis and Dr. Yunong Gao for providing the clinical data.

Author information

Author notes

  1. Tingting Ren

    Present address: Musculoskeleted Tumor Center, Peking University People’s Hospital, Beijing, 100044, China

Authors and Affiliations

  1. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, 52 Fu, cheng Road, Beijing, 100, 142, C, hina

    Tingting Ren, Beihai Jiang, Xiaofang Xing, Lirong Peng, Lin Meng, Huiyu Xu & Chengchao Shou

  2. Core facility of Beijing Cancer Hospital & Institute, Beijing, China

    Bin Dong

Authors
  1. Tingting Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beihai Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaofang Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lirong Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lin Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huiyu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chengchao Shou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chengchao Shou.

Additional information

Tingting Ren, Beihai Jiang, Both authors contributed equally to this work

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ren, T., Jiang, B., Xing, X. et al. Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer. Pathol. Oncol. Res. 15, 555–560 (2009). https://doi.org/10.1007/s12253-009-9153-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-009-9153-1

Keywords

Search

Navigation